What Synaptiq Therapeutics’ SYN-001 acquisition means for 22q11.2 deletion syndrome
Synaptiq Therapeutics acquires SYN-001 and plans a Phase IIb trial for neuropsychiatric symptoms in 22q11.2 deletion syndrome.
Pharma & Biotech